SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is highly active amid discussions surrounding a Department of Justice criminal probe into Fed Chair Jerome Powell, which he has publicly portrayed as political pressure impacting the Federal Reserve's independence. This has ignited heated debate within the community, with some anticipating significant market instability and a potential shift to safe-haven assets, while others see it as a push for faster rate cuts and a challenge to the Fed's authority.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi is trending as investors assess the implications of a proposed cap on credit card interest rates, sparking debate about its potential impact across the fintech lending landscape. The community is actively discussing whether this could create a significant opportunity for SoFi's personal loan segment if traditional banks adjust their credit offerings, or if it poses a challenge, with many believing the cap's passage remains unlikely.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is trending following strong visibility at CES, where it showcased advanced agentic voice and visual AI solutions and announced new partnerships in automotive and robotics. The community is highly engaged, discussing the company's significant growth potential from its proprietary white-label technology and high short interest, despite some recent analyst downgrades.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ faces intense market scrutiny as a DOJ subpoena for Fed Chair Jerome Powell fuels uncertainty around central bank independence and broader economic policy. Community sentiment is sharply divided, with concerns about political interference and upcoming credit card rate caps contrasted by persistent "buy the dip" conviction in technology and growth stocks.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is generating significant buzz as major competitors, including Amazon Pharmacy, expand into the GLP-1 weight loss market with competitively priced oral treatments, intensifying bearish concerns about market share and HIMS's competitive moat. While many anticipate further declines, a strong contingent of bulls points to the company's vertically integrated "lab moat," personalized healthcare strategy, and international expansion as key long-term differentiators, viewing the current downturn as a prime buying opportunity amidst short squeeze potential.

Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The firm offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It also offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. The company was founded by David Brunel and Robert E. Cawthorn in 2005 and is headquartered in Louisville, CO.

Biodesix Inc

Biodesix (BDSX) is drawing significant attention following its preliminary quarterly and full-year results, which reportedly surprised the market with strong revenue and improved adjusted EBITDA. The community is actively debating whether these positive developments, coupled with substantial insider buying and a notably low share float, signal a potential short squeeze or if lingering concerns about the company's cash position and dilution risks will temper sustained upside.

Rich Sparkle Holdings Ltd. engages in the provision of financial printing and corporate services. The firm offers typesetting, proofreading, translation, design, and printing of listing documents, financial reports, fund documents, circulars, and announcements. It also delivers advisory services, such as conducting internal control assessment and environmental, social and governance performance evaluation, and other services including provision of co-working space. The company was founded in 2016 and is headquartered in Hong Kong.

Rich Sparkle Holdings Ltd.

Rich Sparkle Holdings Limited

Rich Sparkle Holdings (ANPA), a microcap Hong Kong-based company, is generating significant buzz following news of its acquisition of TikTok icon Khaby Lame's core company and a recent private placement. The community is highly divided, with many drawing parallels to past 'China pump' stocks, anticipating a massive short squeeze while others caution about the stock's extreme valuation and speculative nature.

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.

Abivax - ADR

Abivax is trending amidst intense takeover speculation, notably involving Eli Lilly, following compelling Phase 3 data for its ulcerative colitis drug, obefazimod. The community is buzzing with discussions about potential significant acquisition offers and the drug's blockbuster market potential, positioning ABVX as a highly sought-after biotech asset. This M&A interest is further amplified by strong analyst confidence in obefazimod's differentiated profile within the competitive inflammatory bowel disease sector.

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Tempus AI Inc. - Ordinary Shares - Class A

Tempus AI Inc

Tempus AI is experiencing significant upward momentum after announcing a record total contract value exceeding $1.1 billion for 2025, fueled by data agreements with over 70 pharmaceutical and biotech companies. This major business development highlights the strength of its AI-driven precision medicine platform, sparking widespread community excitement and further institutional interest in its role in advancing drug discovery and development.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

GLD is trending due to significant market unease following reports of a criminal investigation into the Federal Reserve Chair, intensifying concerns over Fed independence and broader political instability. Safe haven demand, geopolitical tensions, and potential currency debasement are key talking points among investors. While some anticipate volatility from ongoing commodity index rebalancing, others emphasize gold's resilience amid global economic shifts and consistent central bank buying.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity

Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity Viking Therapeutics Announces Publication of Results...

Viking Therapeutics, Inc. (VKTX) Outperforms Broader Market: What You Need to Know

Viking Therapeutics, Inc. (VKTX) reached $31.99 at the closing of the latest trading day, reflecting a +1.07% change compared to its last close.

VKTX Completes Enrollment in Phase I Maintenance Study of Obesity Drug

Viking Therapeutics completes enrollment in a phase I maintenance study of VK2735, testing flexible oral and injectable dosing after initial weight loss in obese adults.

Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet

Based on the average brokerage recommendation (ABR), Viking Therapeutics (VKTX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Here's How Much $100 Invested In Viking Therapeutics 10 Years Ago Would Be Worth Today

Can the US Launch of NVO's Wegovy Pill Reignite Momentum in 2026?

Novo Nordisk shares jump after the U.S. launch of its FDA-approved Wegovy pill, giving the first oral GLP-1 weight-loss drug a chance to revive 2026 momentum.

Viking Therapeutics (NASDAQ:VKTX) CFO Greg Zante Sells 57,661 Shares

Viking Therapeutics, Inc. (NASDAQ:VKTX - Get Free Report) CFO Greg Zante sold 57,661 shares of the company's stock in a transaction on Monday, January 5th. The stock was sold at an average price of...

<ul class="summary-bullets"><li>Regulatory filings showed share sales by Viking’s CEO, CFO and COO on Monday.</li><li>Novo Nordisk announced oral Wegovy pricing starting at $149 a month in the U.S.</li><li>Viking’s lead obesity drug VK2735 is still in Phase 3 clinical trials.</li></ul>Shares of Viking Therapeutics Inc. fell sharply on Monday, logging their worst day in more than four months, after regulatory filings showed significant share sales by the company’s top executives.&nbsp;The stock fell 9.3% to $32.14 in Monday’s regular session before paring some losses with a slight after-hours gain.According to the company’s filings on&nbsp;Monday, Brian Lian, Viking’s president and chief executive officer, sold 233,409 shares, stock worth about $7.7 million. On the same day, Greg Zante, the company’s chief financial officer, sold 57,661 shares valued at roughly $1.9 million, while Marianna Mancini, Viking’s chief operating officer, sold 57,661 shares, also worth about $1.9 million.<h2 class="st-heading-2">Novo’s Wegovy Pricing Adds Competitive Pressure</h2>The insider selling came as investors digested a&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-wegovy-pill-price-149-month-retail-tells-shorts-time-to-give-up/cmxMZLwR4bo">major pricing move by Novo Nordisk</a>, which announced that U.S. customers can obtain the oral version of Wegovy starting at $149 per month. Novo said the 1.5 mg and 4 mg doses would be available to self-paying customers at that price beginning Monday, although the cost of the 4 mg dose will rise to $199 per month from April 15. The company added that higher 9 mg and 25 mg doses are priced at $299 per month, with no promotional offers.Novo also said customers with commercial insurance could pay as little as $25 per month for the oral pill. The announcement followed the FDA approval of oral Wegovy, making it the first oral GLP-1 drug approved for weight loss.<h2 class="st-heading-2">Viking’s Obesity Program</h2>Viking's lead obesity candidate, VK2735, is a dual GLP-1/GIP receptor agonist being developed in both subcutaneous and oral formulations. In November, Viking said it finished enrolling patients ahead of schedule in its Phase 3 Vanquish-1 trial, which is testing a once-weekly injection of VK2735 over 78 weeks in about 4,650 adults who are obese or overweight and have at least one weight-related health condition.The primary endpoint of the study is to measure the change in body weight relative to placebo, while also tracking the proportion of patients who achieve 5%, 10%, 15%, and 20% weight loss. Viking is also running a second Phase 3 trial, Vanquish-2, in overweight or obese patients with type 2 diabetes, with enrollment expected to finish in the first quarter of 2026. Earlier Phase 2 results showed patients lost up to 14.7% of their body weight in 13 weeks, which Viking said met its primary and secondary endpoints.<h2 class="st-heading-2">Wall Street Backs Viking</h2>In October, Canaccord initiated coverage of Viking Therapeutics with a ‘Buy’ rating and a $106 price target, calling Viking “a leader in the obesity drug development space.” The firm expects readouts from Viking’s two Phase 3 trials in 2027 and mid-2028, respectively, and pointed to what he described as “strong” Phase 2 efficacy data from the oral version of VK2735 reported in August. He added that Canaccord believes VK2735 could differentiate on “multiple fronts.”<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for Viking was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/vktx_ss_png_ef1044304f.webp" alt="vktx ss.png" width="972" height="147"><figcaption>VKTX sentiment and message volume as of January 5| Source: Stocktwits</figcaption></figure>One user said&nbsp;they would be a “buyer if this comes down to the mid-20s. Already have a position but would love to add more at a discount.”<stembedurl>https://stocktwits.com/T0THEM00NN/message/640902717</stembedurl>Another user pointed out that the insider selling “kills some buyout chances in near future.”<stembedurl>https://stocktwits.com/GreenHawkz/message/640900403</stembedurl><a href="https://stocktwits.com/symbol/VKTX">Viking’s stock</a> has declined 25% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a person holds a smartphone displaying the logo of Viking Therapeutics on July 19, 2025. (Photo illustration by Cheng Xin/Getty Images)

Viking Therapeutics Stock Suffers Worst Day In Over 4 Months As Top Execs Dump Shares — Novo’s $149 Wegovy Move Looms

Novo’s pricing applies to lower-dose oral Wegovy, with higher doses set at higher monthly prices.

Equity

Marianna Mancini Sells 57,661 Shares of Viking Therapeutics (NASDAQ:VKTX) Stock

Viking Therapeutics, Inc. (NASDAQ:VKTX - Get Free Report) COO Marianna Mancini sold 57,661 shares of the stock in a transaction on Monday, January 5th. The stock was sold at an average price of...

Insider Selling: Viking Therapeutics (NASDAQ:VKTX) CEO Sells 233,409 Shares of Stock

Viking Therapeutics, Inc. (NASDAQ:VKTX - Get Free Report) CEO Brian Lian sold 233,409 shares of Viking Therapeutics stock in a transaction that occurred on Monday, January 5th. The shares were sold...

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Yes — Rates Move Meaningfully Lower

Short-Term Dip, No Lasting Impact

No — Mostly Political Noise

Other – Comment Below

President Trump says he’s directing $200 billion into mortgage bond purchases to bring down rates and improve housing affordability. With questions around execution, authority, and real market impact, do you think this move will actually lower mortgage rates in 2026?

Will Trump’s Mortgage Bond Plan Actually Lower Rates in 2026?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.90	--	--	N/A
Q3 '25	-$0.70	-$0.81	-15.17%	MISSED
Q2 '25	-$0.45	-$0.58	-29.90%	MISSED
Q1 '25	-$0.33	-$0.41	-25.00%	MISSED
Q4 '24	-$0.27	-$0.32	-17.65%	MISSED

VKTX
Viking Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest VKTX News

VKTXViking Therapeutics Inc